解读药物遗传学研究中的P值：对过程和视角的呼吁。 - Suppr

Suppr

超能文献

Interpreting P values in pharmacogenetic studies: a call for process and perspective.

作者信息

Maitland Michael L, Ratain Mark J, Cox Nancy J

出版信息

J Clin Oncol. 2007 Oct 10;25(29):4513-5. doi: 10.1200/JCO.2007.12.7803.

DOI:10.1200/JCO.2007.12.7803

PMID:17925544

Abstract

摘要

相似文献

Interpreting P values in pharmacogenetic studies: a call for process and perspective.

J Clin Oncol. 2007 Oct 10;25(29):4513-5. doi: 10.1200/JCO.2007.12.7803.

Pharmacogenetics in clinical practice: considerations for testing.

Expert Rev Mol Diagn. 2006 Mar;6(2):193-205. doi: 10.1586/14737159.6.2.193.

Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.

Stat Med. 2006 Sep 30;25(18):3081-92. doi: 10.1002/sim.2499.

Pharmacogenetics: the Dx perspective.

Expert Rev Mol Diagn. 2001 Nov;1(4):371-6. doi: 10.1586/14737159.1.4.371.

Pharmacogenetic analysis of clinically relevant genetic polymorphisms.

Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S449-52. doi: 10.1086/431995.

Applications of microarrays and biochips in pharmacogenomics.

Methods Mol Biol. 2008;448:21-30. doi: 10.1007/978-1-59745-205-2_2.

Impact of the human genome on the discovery of immune-modulatory therapeutics.

Curr Opin Investig Drugs. 2006 May;7(5):406-11.

Genome-based pharmacogenetics and the pharmaceutical industry.

Nat Rev Drug Discov. 2002 Jul;1(7):541-9. doi: 10.1038/nrd840.

Reporting and interpretation in genome-wide association studies.

Int J Epidemiol. 2008 Jun;37(3):641-53. doi: 10.1093/ije/dym257. Epub 2008 Feb 11.

Biostatistical aspects of genome-wide association studies.

Biom J. 2008 Feb;50(1):8-28. doi: 10.1002/bimj.200710398.

引用本文的文献

Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives.

Pharmgenomics Pers Med. 2023 Jul 11;16:729-737. doi: 10.2147/PGPM.S361222. eCollection 2023.

Biomarker in Colorectal Cancer.

Cancer J. 2016 May-Jun;22(3):156-64. doi: 10.1097/PPO.0000000000000190.

Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.

Clin Cancer Res. 2013 Oct 15;19(20):5769-76. doi: 10.1158/1078-0432.CCR-13-0774. Epub 2013 Aug 20.

Implications of genome-wide association studies in cancer therapeutics.

Br J Clin Pharmacol. 2013 Sep;76(3):370-80. doi: 10.1111/bcp.12166.

Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?

Clin Cancer Res. 2012 May 15;18(10):2809-16. doi: 10.1158/1078-0432.CCR-11-2445. Epub 2012 Mar 16.

Clinical trials in the era of personalized oncology.

CA Cancer J Clin. 2011 Nov-Dec;61(6):365-81. doi: 10.3322/caac.20135. Epub 2011 Oct 27.

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.

Eur J Clin Pharmacol. 2011 Jul;67(7):693-700. doi: 10.1007/s00228-011-1007-6. Epub 2011 Feb 16.

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Eur J Clin Pharmacol. 2011 May;67 Suppl 1:17-27. doi: 10.1007/s00228-010-0931-1. Epub 2010 Nov 11.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

J Clin Oncol. 2010 Jul 10;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943. Epub 2010 Jun 7.

Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.

Pharmacogenet Genomics. 2010 May;20(5):327-37. doi: 10.1097/FPC.0b013e3283396c4e.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Interpreting P values in pharmacogenetic studies: a call for process and perspective.

J Clin Oncol. 2007 Oct 10;25(29):4513-5. doi: 10.1200/JCO.2007.12.7803.

Pharmacogenetics in clinical practice: considerations for testing.

Expert Rev Mol Diagn. 2006 Mar;6(2):193-205. doi: 10.1586/14737159.6.2.193.

Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.

Stat Med. 2006 Sep 30;25(18):3081-92. doi: 10.1002/sim.2499.

Pharmacogenetics: the Dx perspective.

Expert Rev Mol Diagn. 2001 Nov;1(4):371-6. doi: 10.1586/14737159.1.4.371.

Pharmacogenetic analysis of clinically relevant genetic polymorphisms.

Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S449-52. doi: 10.1086/431995.

Applications of microarrays and biochips in pharmacogenomics.

Methods Mol Biol. 2008;448:21-30. doi: 10.1007/978-1-59745-205-2_2.

Impact of the human genome on the discovery of immune-modulatory therapeutics.

Curr Opin Investig Drugs. 2006 May;7(5):406-11.

Genome-based pharmacogenetics and the pharmaceutical industry.

Nat Rev Drug Discov. 2002 Jul;1(7):541-9. doi: 10.1038/nrd840.

Reporting and interpretation in genome-wide association studies.

Int J Epidemiol. 2008 Jun;37(3):641-53. doi: 10.1093/ije/dym257. Epub 2008 Feb 11.

Biostatistical aspects of genome-wide association studies.

Biom J. 2008 Feb;50(1):8-28. doi: 10.1002/bimj.200710398.

引用本文的文献

Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives.

Pharmgenomics Pers Med. 2023 Jul 11;16:729-737. doi: 10.2147/PGPM.S361222. eCollection 2023.

Biomarker in Colorectal Cancer.

Cancer J. 2016 May-Jun;22(3):156-64. doi: 10.1097/PPO.0000000000000190.

Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.

Clin Cancer Res. 2013 Oct 15;19(20):5769-76. doi: 10.1158/1078-0432.CCR-13-0774. Epub 2013 Aug 20.

Implications of genome-wide association studies in cancer therapeutics.

Br J Clin Pharmacol. 2013 Sep;76(3):370-80. doi: 10.1111/bcp.12166.

Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?

Clin Cancer Res. 2012 May 15;18(10):2809-16. doi: 10.1158/1078-0432.CCR-11-2445. Epub 2012 Mar 16.

Clinical trials in the era of personalized oncology.

CA Cancer J Clin. 2011 Nov-Dec;61(6):365-81. doi: 10.3322/caac.20135. Epub 2011 Oct 27.

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.

Eur J Clin Pharmacol. 2011 Jul;67(7):693-700. doi: 10.1007/s00228-011-1007-6. Epub 2011 Feb 16.

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Eur J Clin Pharmacol. 2011 May;67 Suppl 1:17-27. doi: 10.1007/s00228-010-0931-1. Epub 2010 Nov 11.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

J Clin Oncol. 2010 Jul 10;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943. Epub 2010 Jun 7.

Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.

Pharmacogenet Genomics. 2010 May;20(5):327-37. doi: 10.1097/FPC.0b013e3283396c4e.